Multi-Disciplinary Organization Dedicated to Promoting Advances in
Neuro-Oncology Through Research and Education

SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS

Abstract Deadline: July 10, 2017 11:59pm CST

Read Full Story

Registration Now OPen

SNO Annual Meeting - November 16 - 19, 2017

Read Full Story

Brain Tumor Biorepository Established

Ian's Friends Foundation, Children's Health Care of Atlanta

Read Full Story
View All News


International Meeting on Meningioma

Read Full Story


Mayo Clinic Neuroscience and Oncology Innovation Summit 2017

Read Full Story

Sunrise Sessions and Lunch Tutorials



SNO/ASNO Joint Sesson: New Horizons in PET Imaging in Neuro-Oncology (ASNO/SNO)   

  • Role of amino acid-tracer PET for decision making in neuro-oncology, Joerg-Christian Tonn
  • Usefulness of positron emission tomography (PET) for CNS tumors, Keisuke Miyake
  • Feedback of the PET-imaging to the treatment of malignant brain tumors and radiation injuries, Shin-Ichi Miyatake
  • Simultaneous PET/MRI in clinical neuro-oncology, Ian Law

A "Vagabond Theory" of Glioblastoma: Picking One's Way Through the Brain Microenvironment to Fatal Progression 

  • From niche to milieu, Michael Berens
  • Macro effects of microglia and macrophages, Joanna Phillips
  • Cloak and dagger, Justin Lathia
  • Inside out - The making of the microenvironment of glioblastoma, Jakub Godlewski

Immune Based Therapies for Glioma      

  • Cellular immunotherapy targeting glioblastoma, Duane Mitchell
  • Immune checkpoint inhibitors for malignant gliomas, Michael Lim
  • Immunotherapy targeting glioma neoantigens, Hideho Okada
  • Overcoming immunosuppression in malignant gliomas, Derek Wainwright

Therapeutic Opportunities Presented by Dysregulated Cell Signaling Mechanisms

  • Uncoupling tumor heterogeneity to promote therapeutic sensitivity, Frank Furnari
  • Regulatory circuits in GBM subtypes, Shi-Yuan Cheng
  • Next-generation therapies to treat driver pathways in glioblastoma, William Weiss
  • Metabolic signaling and epigenetic regulation in glioma, Zhimin Lu

Current Update on the Diagnosis and Management of Lower Grade Gliomas        

  • Contemporary molecular classification of lower grade gliomas with implications for diagnosis and grading, Daniel Brat
  • Ancestry of multifocal lower grade gliomas, Joseph Costello
  • Title Pending, Elizabeth Maher
  • Intraoperative IDH status determining extent of resection and outcome, Gelareh Zadeh

Getting More Out of Radiation: Combination Therapy and Dose Escalation           

  • Mechanisms to improve the effect of radiation, Erik Sulman
  • Escalating the dose to improve the outcome of patients with glioblastoma, Christina Tsien
  • Multi-arm & adaptive trials to improve the efficacy of radiation, Brian Alexander
  • Blood brain barrier penetration in radio-sensitivity, Jann Sarkaria



Novel Metabolic Targets and Their Genetic Basis in Glioma          

  • Metabolic profiling of glioma, Sabrina Ronen
  • Temozolomide and metabolism in IDH1 mutant glioma, Daniel Cahill
  • Lipogenesis and glioblastoma, Deliang Guo
  • Metabolic dependencies induced by IDH1 mutation, Samuel McBrayer

EANO-SNO Joint Sunrise Session: Glioblastoma in the Elderly: Solid Conclusions Built on Shifting Sand?
Wolfgang Wick, Tracy Batchelor, Co-Chairs

  • Specific Requirements of elderly patients, Roberta Rudà
  • Update on molecular biomarkers in the elderly, Jason Huse
  • Surgery in the elderly glioma patient, Colin Watts
  • Standard of care postsurgical therapy 2017, James Perry

Using Patient Reports as a Measure of Net Clinical Benefit            

  • Integrating patient report measures into neuro-oncology clinical practice: Opportunities for targeted interventions, Christina Amidei
  • Understanding the natural history of rare CNS tumors through patient self-report and web-based portals, Terri Armstrong
  • Applying patient report measures as quality metrics in pediatric brain tumor care, Jin-Shea Lai
  • Patient report measures in research, Martin Taphoorn

Histone Mutations in Pediatric Gliomas   

  • Oncohistones: Professional hijackers of the epigenome, Nada Jabado
  • The ABCs of chromatin biology and biochemical insights into the mechanisms of histone mutations, Peter Lewis
  • Diagnostic and prognostic implications of histone mutations in clinical practice, Cynthia Hawkins
  • Targeting histone mutations in the clinic, are we there yet?, Oren Becher

Brain Metastases            

  • Microenvironmental interactions in brain metastasis, Adrienne Boire
  • Brain metastasis genomics, Priscilla Brastianos
  • Targeted therapy in brain metastasis, Manmeet Ahluwalia
  • Brain metastasis-microenvironment interactions: an emerging source of innovative therapies, Manuel Valiente

Tumor-related Epilepsy 

  • EEG monitoring and brain mapping in TRE, Jeffrey Politsky
  • Epidemiology and etiology of TRE, Joon Uhm
  • Medical/pharmacologic considerations in TRE, Patrick Wen
  • Systems biology and surgical treatment of TRE, Sandeep Mittal



Circulating Biomarkers  -Technology and Application       

  • Biomarkers and effectors of the cellular interactome in cancer, Janusz Rak
  • Glioblastoma transgenic mouse models for advance in biomarker studies, Alain Charest
  • Immune evasion mediated by PD-L1 on glioblastoma-derived exosomes, Sean Lawler
  • Heterogeneity of EVs cargo in the progression and therapeutic response in glioblastoma, Agnieszka Bronisz

Clonal Evolution of Glioblastoma              

  • Clonal evolution and prediction of pharmacologic vulnerabilities of human glioma, Antonio Iavarone
  • Deciphering single-cell programs in adult and pediatric gliomas, Mario Suva
  • Deconstructing clonal composition in glioma through multiomic analysis of serial sections, Michael Oldham
  • Integrated model of clonal evolution, Joseph Costello

Viral Therapy: Advances from Bench to Bedside 

  • Determining the optimal dose for phase II/III studies of OV: the lesson of poliovirus, John Sampson
  • Oncolytic adenoviral therapy for glioma and use of adjuvant treatments, Frederick Lang
  • Toca-511 trials and implications of survival-related mRNA expression profiles in OV trials for glioma, Noriyuki Kasahara
  • Oncolytic HSV for glioma-potential for childhood cancers and use of immunogene therapy, James Markert

Discovery, Characterization and Functionalizing Novel Glioma Genes        

  • Overview of Glioma Epidemiologic Studies, Melissa Bondy
  • Identification of germline mutations in glioma families identified through whole genome sequencing, Matthew Bainbridge
  • Identification of novel SNPS identified through GWAS analysis, Margaret Wrensch
  • Developing the pipeline using CRISPR to functionalize genes identified through genetic screening, Benjamin Deneen

Meningiomas: Molecular Advances Toward Developing Targeted Therapies          

  • Methylation classifier for meningiomas: beyond WHO grading, Kenneth Aldape
  • Lessons learned from genomic landscape of atypical meningiomas, Ian Dunn
  • RNA pathway analysis directing therapeutic strategies in meningiomas, Gelareh Zadeh
  • Challenges and opportunities in clinical trials for meningiomas, Michael Jenkinson

Developing Cancer Stem Cell Targeting Strategies             

  • Attenuating cell-cell communication in CSCs via drug repurposing strategies, Justin Lathia
  • Targeting neurotransmission to compromise self-renewal, Peter Dirks
  • Sexual dimorphism in CSC drug responses, Joshua Rubin
  • Using pluripotent stem cells to model CSCs and identify novel drug targets, Viviane Tabar



12:15pm – 1:15pm



Epigenetics of CNS malignancies

  • Defining the non-coding epigenome of glioma CpG Island Methylator Phenotype (G-CIMP), Houtan Noushmehr
  • Disentangling developmental and oncogenic epigenetic states of medulloblastoma subtypes, Paul Northcott
  • Histone modifications in pediatric brain tumors, Sriram Venneti

Palliative Care - Health Outcome Measures and Communication Strategies in Neuro-Oncology

  • Introduction to palliative care in neuro-oncology and health outcome measures, Tobias Walbert
  • Communication strategies in neuro-oncology, Alan Carver
  • Palliative care integration into neuro-oncology, Jennifer Philip

Emerging Functional and Genomic Single Cell Technologies

  • Single cell mass as a novel biomarker of drug response in brain tumors, Keith Ligon
  • Single cell cloning analysis of tumors and their treatment hierarchies using optical bar coding, Katrin Lamszus
  • EvoSeq: A molecular time machine to characterize resistance at a single cell level, Pratiti Bandopadhayay

Clinical Trials - A Primer for Junior Investigators

  • Design of phase 0 and I trials, Patrick Wen
  • Phase II Trials, Timothy Cloughesy
  • Basic statistics for clinical trials, Karla Ballman


SATURDAY, NOVEMBER 18                       

Introduction to CRISPR-based Technologies         

  • CRISPRi and CRISPRa for programmable transcriptional control, Daniel Lim
  • Opportunities and challenges of CRISPR-Cas gene editing, Jennifer Doudna
  • CRISPR/Cas9 for genome editing, Alex Marson

Basic Science in Neuro-Oncology for the Clinician             

  • Biology of primary brain tumors – The basics, Vinay Puduvalli
  • Basic immunology for the clinician, Amy Heimberger
  • Genomics and Epigenomics in neuro-oncology: making sense of the maze, Russell Pieper

Quantitative Biology in Neuro-Oncology

  • Public portal pearls and pitfalls: a hitchhiker’s guide to available data and analysis resources, Cameron Brennan
  • Large scale systems biology in brain cancer genomics, Michele Ceccarelli
  • Functional characterization of glioma cancer genes, Antonio Iavarone

Surgical Trials: From Design to Regulatory Approval         

  • Clinical trial design for neurosurgeons, Michael Vogelbaum
  • Getting FDA approval for devices and diagnostic tools (5-ALA), Constantinos Hadjipanayis
  • Phase 0 clinical trials and associated opportunities for neurosurgeons, Nader Sanai